Minor extended-spectrum -lactamases
Expert Review of Anti-Infective Therapy, cilt.8, sa.11, ss.1251-1258, 2010 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 8 Sayı: 11
- Basım Tarihi: 2010
- Doi Numarası: 10.1586/eri.10.119
- Dergi Adı: Expert Review of Anti-Infective Therapy
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1251-1258
- Anahtar Kelimeler: beta-lactamase, Acinetobacter, antimicrobial drug resistance, Escherichia coli, Pseudomonas aeruginosa
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Over the last few decades, various extended-spectrum -lactamases (ESBLs), which are remotely related to the classical TEM and SHV families, have emerged. Among these, CTX-M, VEB and PER variants are of particular interest due to their widespread dissemination. This article will focus on these emerging ESBLs. CTX-M was first identified from an Escherichia coli strain in Germany and since then, a rapidly growing family of ESBLs has formed worldwide. There are now more than 90 CTX-M variants. VEB-1 ESBL is widespread in Southeast Asia. It was first identified in an E. coli strain isolated from a Vietnamese boy in 1996. After the initial discovery, it spread to other species. PER-1, now reported from various continents, was restricted to Turkish hospitals for years after the first identification in a strain of Pseudomonas aeruginosa in 1993. The worldwide dissemination of ESBLs is a healthcare crisis that deserves special attention. © 2010 Expert Reviews Ltd.